Osiris: Smith & Nephew moves further into regenerative medicine with $660M purchase of Osiris

Smith & Nephew has moved to absorb regenerative medicine developer Osiris Therapeutics in a $660 million deal that the company hopes will expand and accelerate its wound care business.